alexa Acute myelogenous leukemia | Spain | PDF | PPT| Case Reports | Symptoms | Treatment

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Recommended Conferences

Read more

Acute Myelogenous Leukemia

  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger
  • Acute myelogenous leukemia

    A life-threatening disorder that predominantly occurs in older adults. Many subtypes exist, of which acute promyelocytic leukaemia merits specific management. A total of 1,331 cases of MMs were diagnosed in the province of Girona from 1994 to 2008: 718 men (53.9%) and 613 women (46.1%). Acute myeloid leukemia (AML) accounted for 24.0% (319 of 1,331), MDS 34.4% (458 of 1,331), MPN 36.7% (489 of 1,331) including chronic myeloid leukemia (CML), and myelodysplastic/myeloproliferative neoplasms (MDS/MPN) for 4.9% (65 of 1,331).

  • Acute myelogenous leukemia

    symptoms: Patients with AML typically present with a normocytic, normochromic anemia that can vary in severity. This anemia worsens with induction chemotherapy and is managed primarily with blood transfusions. There is no role for the use of erythropoietic stimulating agents during induction therapy of AML.The threshold for transfusion of packed red blood cells varies with patient age, symptoms, and the presence of medical comorbidities. In general, most centers recommend transfusion to asymptomatic patients with a hemoglobin ≤8 g/dL (5 mmol/liter).

  • Acute myelogenous leukemia

    Therapeutic aspects: A number of chemotherapy medications are effective against AML. The goal of treatment is to kill the malignant cells without damaging the residual normal bone marrow cells. Studies are underway to find the best medicines, doses, and treatment schedules for AML. Researchers have discovered that the genetic makeup of the abnormal myeloid cells can vary, which affects how you respond to treatment. Your treatment can be tailored based upon a careful analysis of your genetic material.

Expert PPTs

Speaker PPTs

 

High Impact List of Articles

Conference Proceedings

adwords